Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.32 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6762871 | 0.96 | NAMPT (0.40) | NAMPTALDH1A1SMN1; SMN2PTK2POLB | |
| SCHEMBL6948898 | 0.89 | MAOB (0.36) | NAMPTMAOBLDHANTRK3NTRK2 | |
| SCHEMBL5189062 | 0.84 | NAMPT (0.41) | NAMPTALDH1A1SMN1; SMN2HPGDKDM4E | |
| SCHEMBL5444456 | 0.84 | NAMPT (0.41) | NAMPTALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL5236831 | 0.80 | L3MBTL1 (0.42) | NAMPTALDH1A1SMN1; SMN2POLBTDP1 | |
| SCHEMBL5233483 | 0.78 | POLB (0.48) | SMN1; SMN2POLBMAPT | |
| SCHEMBL5233488 | 0.78 | POLB (0.48) | SMN1; SMN2POLBMAPT | |
| SCHEMBL5238254 | 0.78 | POLB (0.48) | SMN1; SMN2POLBMAPT | |
| SCHEMBL16931551 | 0.77 | CDK5 (0.36) | NAMPTALDH1A1PTK2L3MBTL1HPGD | |
| SCHEMBL4899883 | 0.77 | BRD4 (0.47) | ALDH1A1SMN1; SMN2HPGDMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754705-A2 | Antagonists for treatment of CD11/CD18 adhesion receptor mediated disorders | Genentech, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | claimed |
| US-6599918-B2 | Inhibit Factor Xa Factor IIa (thrombin) | AVENTIS PHARMACEUTICALS INC. | 2003-07-29 | — | — | US | claimed |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | AVENTIS PHARMACEUTICALS INC. | 2002-12-19 | — | — | US | claimed |
| EP-3710428-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-25 | — | — | EP | disclosed |
| CN-121045114-A | Compound TBFC-I and preparation method and application thereof | 农业农村部规划设计研究院 | 2025-12-02 | — | — | CN | disclosed |
| US-20240392220-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-09-19 | — | — | US | disclosed |
| EP-4408967-A1 | BRANDY REPLICAS | AVA FOOD LABS, INC. (US) | 2024-08-07 | — | — | EP | disclosed |
| CN-118339274-A | Brandy replica | 艾娃食品实验室股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-112204009-B | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2024-05-07 | — | — | CN | disclosed |
| CN-115943957-B | Application of TBFC in preparation of medicines for preventing and treating bacterial diseases | 北京景霁智惠科技有限公司 | 2024-01-26 | — | — | CN | disclosed |
| EP-0725775-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5484944-A | ANXIETY, SLEEP, MEMORY | NEUROGEN CORPORATION (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1995011885-A1 | CERTAIN FUSED PYRROLECARBOXANILIDES; A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 1995-05-04 | — | — | WO | disclosed |
| US-4336202-A | 1,3-Cyclohexanedione derivatives | KURARAY CO., LTD. (JP) | 1982-06-22 | — | — | US | disclosed |
| EP-0041656-A2 | Cyclohexanone derivatives and preparation thereof | KURARAY CO., LTD. (JP) | 1981-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240307382-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | NAMPT 2047/4885ALDH1A1 3433/4885SMN1; SMN2 2486/4885 |
| US-20020193410-A1 | Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benzopyrans | F2, TFPI, F3 | NAMPT 2067/4885ALDH1A1 1396/4885SMN1; SMN2 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.